Christos Apostolidis

This inventor holds 6 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 3 EPO patents. Top assignees: European Community, European Community (Ec), National Institute of Health and Medical Research. Active years: 2001-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christos Apostolidis. Retrieved from https://idiyas.com/inventor/christos-apostolidis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 1)

% Patents Active = 66.7

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 36(Granted Patents)

Company Filing History:

European Community (Ec)

patents

1 out of 1,853

National Institute of Health and Medical Research

patents

4. 1 out of 14

The European Atomic Energy Community (Euratom), Represented by the European Commission

patents

5. 1 out of 4

The European Community, Represented by the European Commission

patents

6. 1 out of 34

Universitat Heidelberg

patents

where one patent can have more than one assignee

Years Active: 2001-2021

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10980901 - Treatment of PMSA expressing cancers (2021-04-20),

2. 7794691 - Radionuclides for medical use (2010-09-14),

3. 7132513 - Bifunctional chelating agent (2006-11-07),

4. 7045606 - Bifunctional chelating agent for actinium (2006-05-16),

5. 6485695 - Method and apparatus for preparing Bi-213 for human therapeutic use (2002-11-26),

6. 6299666 - Method for producing Ac-225 by irradiation of Ra-226 with protons (2001-10-09),

Title: Christos Apostolidis: Innovator in Radiopharmaceuticals

Introduction

Christos Apostolidis is a prominent inventor based in Heidelberg, Germany. He has made significant contributions to the field of radiopharmaceuticals, holding a total of six patents. His work focuses on innovative methods for treating various cancers and utilizing radionuclides in medical applications.

Latest Patents

One of his latest patents is titled "Treatment of PMSA Expressing Cancers." This invention relates to a method for treating cancers that express PSMA, involving the administration of Ac-225-radiopharmaceuticals in effective dosages tailored to the patient's body weight. Another notable patent is "Radionuclides for Medical Use," which outlines methods for using Th-226 and its mother radionuclides in medicine. These radionuclides are particularly effective for therapeutic, diagnostic, prophylactic, and pain palliation purposes.

Career Highlights

Throughout his career, Christos has worked with the European Community, contributing to advancements in medical technology and treatment methodologies. His innovative approaches have garnered attention in the medical field, particularly in oncology.

Collaborations

Christos has collaborated with notable professionals in his field, including Roger Molinet and Willem Janssens. These partnerships have further enhanced his research and development efforts in radiopharmaceuticals.

Conclusion

Christos Apostolidis stands out as a key figure in the development of radiopharmaceuticals, with a focus on innovative cancer treatments. His contributions continue to impact the medical community positively.

Profile summary based on public USPTO records.